Recent advances in the prevention of respiratory syncytial virus in pediatrics

Madeline A. Lipp,Kerry M. Empey
DOI: https://doi.org/10.1097/mop.0000000000001336
2024-03-07
Current Opinion in Pediatrics
Abstract:Respiratory syncytial virus (RSV) is a ubiquitous virus and the leading cause of pediatric hospitalization in the United States. Prevention strategies are key for reducing the burden of RSV. Several new agents aimed at preventing RSV in infants and children were FDA-approved in 2023, and many more are in the development pipeline. This review highlights new developments in RSV prevention in pediatric patients and the important safety considerations for clinical trials.
pediatrics
What problem does this paper attempt to address?